Peptide Comparison
CJC-1295 vs MK-677
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
GH secretagogues combined with exogenous HGH: Moderate-High risk per peptide research literature. Negative feedback via somatostatin/IGF-1; risk of pituitary suppression; diminishing returns on GH output.
Data-derived verdict
MK-677 has stronger documented evidence (Phase 3 (not approved)) than CJC-1295 (Anecdotal + Phase 2 (DAC)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. CJC-1295 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: water retention. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| CJC-1295 | MK-677 | |
|---|---|---|
| Class | GHRH analog (no-DAC or DAC forms) | Oral non-peptide ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life | GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine |
| Route | SC injection | Oral |
| Half-life | No-DAC ~30 min / DAC ~8 days | ~24 hrs |
| Dosage (research) | No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) | 12.5 mg oral daily (community starting dose to mitigate water retention and appetite increase, escalate to label dose 25 mg/day per MK-0677-014 Phase 3 protocol) |
| Evidence tier | Anecdotal + Phase 2 (DAC) | Phase 3 (not approved) |
| Research depth | 44 indexed | 120 indexed |
| Availability | Compounding Restricted | Research Chemical |
| Reported risks | Water retention; numbness/tingling; elevated IGF-1; injection site reactions | Increased hunger; water retention; insulin resistance risk; lethargy; CHF risk (elderly trials) |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CJC-1295 or MK-677?
MK-677 has stronger documented evidence (Phase 3 (not approved)) than CJC-1295 (Anecdotal + Phase 2 (DAC)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. CJC-1295 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between CJC-1295 and MK-677?
CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); MK-677 is classed as Oral non-peptide ghrelin receptor agonist. Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; MK-677, GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine. Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; MK-677, ~24 hrs. Routes in published studies: CJC-1295, SC injection; MK-677, Oral.
Which has stronger evidence, CJC-1295 or MK-677?
MK-677 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 44 indexed studies. MK-677 is graded Phase 3 (not approved), with 5 cited sources on its reference page and 120 indexed studies.
Which is more accessible, CJC-1295 or MK-677?
Neither CJC-1295 nor MK-677 is an FDA-approved drug. Catalog status: CJC-1295, Compounding Restricted; MK-677, Research Chemical. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn. FDA lists MK-677 in category 2 of its bulk-substance compounding policy (503A; 503B, added 503A: September 29, 2023 503B: December 29, 2022).
Are CJC-1295 and MK-677 ever combined?
CJC-1295 and MK-677 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…